Table 2.
Meta-analysis of 14 studies testing pituitary antibodies prevalence in pituitary adenoma patients and in controls
| Year | First author | Method | OR | 95% Conf. interval | % weight |
|---|---|---|---|---|---|
| 1987 | Scherbaum | IF | 36.12 | 2.08–626.5 | 2.55 |
| 1988 | Komatsu | IF | 7.93 | 0.38–162.1 | 2.99 |
| 1993 | Mau | IB | 18.2 | 0.67–494.8 | 1.32 |
| 1998 | Crock | IB | 2.35 | 0.56–9.84 | 15.35 |
| 1998 | Yabe | IB & ELISA | 0.26 | 0.01–4.61 | 21.41 |
| 2000 | Kikuchi | IB & ELISA | 9.77 | 4.20–22.7 | 15.67 |
| 2002 | Keda | ELISA | 6.88 | 1.73–27.42 | 10.6 |
| 2003 | Tanaka | ITT | 18.86 | 3.15–112.72 | 3.27 |
| 2003 | De Bellis | IF | 10.28 | 1.86–56.72 | 5.53 |
| 2003 | Tatsumi | ITT | 77.34 | 4.39–1360 | 1.29 |
| 2008 | Lupi | IB | 2.69 | 0.15–46.26 | 3.59 |
| 2009 | Lupi (current study) | IF | 7.35 | 2.11–25.64 | 16.34 |
| 2002 | Tanaka | ITT | Excluded | ||
| 2007 | De Bellis | IF | Excluded | ||
Mantel-Haenszel pooled odds ratio = 7.02 (95% confidence interval from 4.9 to 11.6). IF, immunofluorescence; IB, immunoblotting; ELISA, Enzyme-linked immunosorbent assay; ITT, in vitro transcription translation.